Boundless Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $58.7M
- Price
- $2.58
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.77%
- Volume
- 9.6K
About
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Quick stats
Shares outstanding22.7M
Computed float12.1M
Float / shares53.2%
Cash runway (months)19.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001782303
Websitehttps://boundlessbio.com
AI Summary
AI-generated1/19
majorbullishexecutive change
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
Serapha Bio named Kenneth T. Mills as CEO and board member and appointed a full senior leadership team, including Daphne Karydas as President and CFO, Weston Miller as CMO, Nina Hunter as Chief Development Officer and Shiva Fritsch as Chief Corporate Affairs Officer.
The company reaffirmed that its merger with Boundless Bio (Nasdaq: BOLD) remains on track to close in Q4 2026, supported by roughly $230 million in committed pre-closing private investments co-led by RTW Investments and RA Capital, with about $138 million already funded and approximately $92 million more expected at closing. The combined company will trade on Nasdaq under the ticker AATD, subject to approval.
Lead asset SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency, has FDA IND clearance plus orphan drug and RMAT designations, with a Phase 2/3 trial slated to begin in late 2026 or early 2027 following positive investigator-initiated trial data presented at the ERS Congress.
Red flags
- merger closing remains subject to stockholder approval of both companies, S-4 effectiveness and Nasdaq approval of the AATD ticker
- SERP-01 proof-of-concept data comes from an early-stage investigator-initiated trial with limited patients that is not designed to support regulatory approval
- forward-looking statements disclose the combined company's need for substantial additional funding
- SERP-01 relies on intellectual property licensed from YolTech Therapeutics
- cash dividend to pre-merger BOLD stockholders and ownership percentages may change based on closing adjustments